Moderna Stock News

A new strain of COVID-19 first discovered in South Africa was declared a variant of concern by the World Health Organization on Friday. Here''s how the pharmaceutical industry plans to address the latest coronavirus curve ball. Vaccine makers are already pivoting their efforts to combat the new variant: testing higher doses of booster shots, designing new boosters that anticipate strain mutations, and developing omicron-specific boosters. In a statement sent to NPR, Moderna said it has been working on a comprehensive strategy to predict variants of concern since the beginning of 2021. One approach is to double the current booster from 50 to 100 micrograms. Secondly, the vaccine maker has been studying two booster vaccines that are designed to anticipate mutations like those found in the omicron variant. The company also said it will ramp up efforts to make a booster candidate that specifically targets omicron. "From the beginning, we have said that as we seek to defeat the pandemic, it is imperative that we are proactive as the virus evolves," said Moderna CEO Stéphane Bancel. "The mutations in the Omicron variant are concerning and for several days, we have been moving as fast as possible to execute our strategy to address this variant." Pfizer and BioNTech told Reuters that it expects more data about the omicron variant to be collected within two weeks.

Hungarian FM Peter Szijjarto told RT he''s ?frustrated? with Western officials playing politics with Russia''s Sputnik V, world''s first registered Covid vaccine. He says they can?t bring themselves to admit publicly it''s ?the best.? The European Medicines Agency (EMA) has approved vaccines by Pfizer, Moderna, AstraZeneca, and Janssen, yet Russia''s Sputnik V is still awaiting the agency''s nod despit

Hungarian FM Peter Szijjarto told RT he''s ?frustrated? with Western officials playing politics with Russia''s Sputnik V, world''s first registered Covid vaccine. He says they can?t bring themselves to admit publicly it''s ?the best.? The European Medicines Agency (EMA) has approved vaccines by Pfizer, Moderna, AstraZeneca, and Janssen, yet Russia''s Sputnik V is still awaiting the agency''s nod despit

The manufacturers of Americas most used COVID-19 vaccines insist they have plans in place to quickly adapt to potential challenges presented by the new omicron variant.

Moderna to Test Variant-Specific Vaccine Candidate Morningstar.com

The main manufacturers of vaccines against COVID-19 In the West, including Americans Pfizer, Moderna and Johnson & Johnson, reported Friday that they are already testing

PFIZER and Moderna are reportedly capable of updating their COVID-19 vaccines as the new Omicron strain has sparked fear across the world.

Moderna Inc (MRNA) shares closed today 20.6% higher than it did at the end of yesterday. The stock is currently up 215.5% year-to-date, up 201.9% over the past 12 months, and up 1672.2% over the past five years. Today, the Dow Jones Industrial Average fell 2.5%, and the S&P 500 fell 2.2%. Trading Activity Shares traded as high as $350.15 and as low as $258.09 this week.Shares closed 33.7% below its 52-week high and 221.1% above its 52-week low.Trading volume this week was 66.2% lower than the 10-day average and 64.6% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price beats the S&P 500 Index today, beats it on a 1-year basis, and beats it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, beats it on a 1-year basis, and beats it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector today, beats it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -23420.1% The company's stock price performance over the past 12 months beats the peer average by 2054.9% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is 377.0% higher than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

THE HAGUE: The European Union''s drug regulator said on Friday (Saturday in Manila) that it was closely monitoring the new B.1.1.529 Covid-19 variant, but it was too soon to tell if updated vaccines would be needed. The European Medicines Agency (EMA) said it needed more details to see if the strain, which has "numerous mutations," could evade the current four jabs authorized for the bloc. "We are closely monitoring the newly emerged B.1.1.529 variant which presents numerous mutations in the Covid-19 spike protein," the Amsterdam-based EMA said in a statement to Agence France-Presse. "Current information is insufficient to determine if this variant is going to spread significantly and to what extent it may evade the immunity received with vaccines." It added: "EMA considers it premature at the moment to foresee the need of an adapted vaccine with a different composition in order to tackle this emerging variant." The EU has reacted with concern to news of the new strain, proposing that member states stop all flights to and from southern African where it was first discovered.

Paying attention to the Omicron variant might get more people vaxxed, and if so, a good thing.You never know what pushes people to roll up their sleeve, and sometimes just having COVID in the news is enough. So far, South Africa is saying their hospitalized patients are those not fully vaccinated, and theres not yet any data to suggest vaccines are failing. if youre concerned make sure youre fully (three shot) vaccinated) and consider the three shots the primary series. Dr @mvankerkhove gives an update on #COVID19 virus variant B.1.1.529, during the #AskWHO session on 25 November 2021 pic.twitter.com/ZpflfEYzW9 World Health Organization (WHO) (@WHO) November 25, 2021 Kai Kupferschmidt /Twitter: This pandemic has been all about communicating uncertainty and it doesnt get more uncertain than early data on new variants. So a few things to keep in mind the next few days and weeks as the picture around B.1.1.529 becomes clearer and why its right to be concerned Most importantly: We will learn a lot in the coming days but getting good answers takes time, science takes time.

The main producers of the COVID vaccines are evaluating the effectiveness of their vaccines against the new Omicron variant. The South African variant of the virus, given the name of Omicron by the WHO, is forcing Pfizer, Moderna and Johnson & Johnson (known as Janssen in Europe) to question the effectiveness of their vaccines. The [] The post Effectiveness of COVID Vaccines against New Omicron Variant appeared first on Euro Weekly News Spain .

With each passing hour, new restrictions were being slapped on travel from countries in southern Africa as the world scurried Saturday to contain a new variant of the coronavirus that has the potential to be more resistant to the protection offered by vaccines. A host of countries, including Australia, Brazil, Canada Iran, Japan, Thailand and the United States, joined others, including the European Union and the U.K. in impose restrictions on southern African countries in response to warnings over the transmissability of the new variant against the advice of the World Health Organization. Despite the shutdown of flights, there was increasing evidence that the variant is already spreading. Cases have been reported in travelers in Belgium, Israel and Hong Kong, and Germany also has a probable case. Dutch authorities are checking for the new variant after 61 passengers on two flights from South Africa tested positive for COVID-19. The global health body has named the new variant omicron, labeling it a variant of concern because of its high number of mutations and some early evidence that it carries a higher degree of infection than other variants.

Leading drug maker Moderna started to experiment adding booster shots to its mRNa- technology to detect the impact of the booster shots on the Omicron. The test aimed to check the impact of the booster vaccine doses on neutralise the new strain that carried 32 mutations in its protein spike. It began by testing three []

Pharmaceutical companies have sprung into action to look into vaccine protection against the new coronavirus variant first detected in South Africa, which is raising concerns across the world. American pharmaceutical company Moderna announced on Friday it is working to address the new omicron variant, which is potentially more infectious than the currently dominating delta variant []